

# ForPatients

by Roche

Multiple Sclerosis (MS) Relapsing Multiple Sclerosis (RMS)

## Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

**Trial Status**

Active, not recruiting

**Trial Runs In**

2 Countries

**Trial Identifier**

NCT04377555 ML42071

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The study plans to enroll approximately 150 participants (75 AA and 75 HA) with 50 participants enrolled in a CSF sub-study.

**Genentech, Inc.**

Sponsor

**Phase 4**

Phase

---

**NCT04377555 ML42071**

Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**

All

**Age**

>=18 Years & <= 65 Years

**Healthy Volunteers**

No

---